These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38293275)

  • 1. Erratum to "Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD" [World Allergy Organ (2023) 100817].
    Tepetam FM; Özden Ş; Kılıç FK; Örçen C; Yakut T
    World Allergy Organ J; 2024 Feb; 17(2):100861. PubMed ID: 38293275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does NSAID exacerbated respiratory disease (N-ERD) accompanying severe asthma affect biological treatment response? Efficacy of omalizumab and mepolizumab in N-ERD.
    Tepetam FM; Özden Ş; Kılıç FK; Örçen C; Yakut T
    World Allergy Organ J; 2023 Sep; 16(9):100817. PubMed ID: 37771938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease.
    Cihanbeylerden M; Tuncay G; Kayıkçı H; Damadoglu E; Karakaya G; Kalyoncu AF
    Int Arch Allergy Immunol; 2024 Jun; ():1-6. PubMed ID: 38865992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in Olfaction in Patients With CRSwNP and Severe Asthma Taking Anti-IgE and Anti-IL-5 Biologics: A Real-Life Study.
    Barroso B; Valverde-Monge M; Alobid I; Olaguibel JM; Rial MJ; Quirce S; Arismendi E; Barranco P; Betancor D; Bobolea I; Cárdaba B; Cruz Carmona MJ; Curto E; Domínguez-Ortega J; González-Barcala FJ; Martínez-Rivera C; Mahíllo-Fernández I; Muñoz X; Picado C; Plaza V; Rodrigo Muñoz JM; Soto-Retes L; Valero A; Del Pozo V; Mullol J; Sastre J
    J Investig Allergol Clin Immunol; 2023 Feb; 33(1):37-44. PubMed ID: 35416154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
    Van Broeck D; Steelant B; Scadding G; Hellings PW
    Front Allergy; 2023; 4():1080951. PubMed ID: 37123562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Omalizumab in NSAID-Exacerbated Respiratory Disease: A Narrative Review.
    Taniguchi M; Heffler E; Olze H; White A; Côrte-Real J; Olsson P; Lazarewicz S
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2570-2578. PubMed ID: 35764285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab-Induced Aspirin Tolerance in Nonsteroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease Patients Is Independent of Atopic Sensitization.
    Quint T; Dahm V; Ramazanova D; Arnoldner MA; Kurz H; Janik S; Brunner PM; Knerer-Schally B; Weninger W; Griss J; Ristl R; Schneider S; Bangert C
    J Allergy Clin Immunol Pract; 2022 Feb; 10(2):506-516.e6. PubMed ID: 34678497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NSAID-exacerbated respiratory disease: a population study.
    Andersén H; Ilmarinen P; Honkamäki J; Tuomisto LE; Hisinger-Mölkänen H; Backman H; Lundbäck B; Rönmark E; Haahtela T; Sovijärvi A; Lehtimäki L; Piirilä P; Kankaanranta H
    ERJ Open Res; 2022 Jan; 8(1):. PubMed ID: 35083326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab in patients with NSAIDs-exacerbated respiratory disease.
    Forster-Ruhrmann U; Stergioudi D; Pierchalla G; Fluhr JW; Bergmann KC; Olze H
    Rhinology; 2020 Jun; 58(3):226-232. PubMed ID: 32077449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
    Kowalski ML; Agache I; Bavbek S; Bakirtas A; Blanca M; Bochenek G; Bonini M; Heffler E; Klimek L; Laidlaw TM; Mullol J; Niżankowska-Mogilnicka E; Park HS; Sanak M; Sanchez-Borges M; Sanchez-Garcia S; Scadding G; Taniguchi M; Torres MJ; White AA; Wardzyńska A
    Allergy; 2019 Jan; 74(1):28-39. PubMed ID: 30216468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can nasal acetylsalicylic acid challenge predict the severity of non-steroidal anti-inflammatory drugs (NSAIDs)-exacerbated respiratory disease (N-ERD)?
.
    Förster-Ruhrmann U; Tietz AK; Kim J; Liebers U; Szczepek AJ; Olze H
    Allergol Select; 2020; 4():135-143. PubMed ID: 33393939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.
    Jakiela B; Soja J; Sladek K; Przybyszowski M; Plutecka H; Gielicz A; Rebane A; Bochenek G
    J Allergy Clin Immunol; 2021 Apr; 147(4):1269-1280. PubMed ID: 32810516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
    Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
    Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inheritance of NSAID-Exacerbated Respiratory Disease.
    Suikkila A; Lyly A; Hafrén L; Saarinen R; Klockars T
    Otolaryngol Head Neck Surg; 2023 Mar; 168(3):540-543. PubMed ID: 35639475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erratum to "IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper" [World Allergy Organ J 13/2 (2020) 100080].
    Ansotegui IJ; Melioli G; Canonica GW; Caraballo L; Villa E; Ebisawa M; Passalacqua G; Savi E; Ebo D; Gómez RM; Luengo Sánchez O; Oppenheimer JJ; Jensen-Jarolim E; Fischer DA; Haahtela T; Antila M; Bousquet JJ; Cardona V; Chiang WC; Demoly PM; DuBuske LM; Ferrer Puga M; Gerth van Wijk R; González Díaz SN; Gonzalez-Estrada A; Jares E; Kalpaklioğlu AF; Kase Tanno L; Kowalski ML; Ledford DK; Monge Ortega OP; Morais-Almeida M; Pfaar O; Poulsen LK; Pawankar R; Renz HE; Romano AG; Rosário Filho NA; Rosenwasser L; Sánchez Borges MA; Scala E; Senna GE; Sisul JC; Tang MLK; Yu-Hor Thong B; Valenta R; Wood RA; Zuberbier T
    World Allergy Organ J; 2021 Jul; 14(7):100557. PubMed ID: 34221218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets.
    Laidlaw TM; Levy JM
    Curr Allergy Asthma Rep; 2020 Mar; 20(4):10. PubMed ID: 32172365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of omalizumab and mepolizumab treatment efficacy in patients with atopic and eosinophilic "Overlap" severe asthma: Biological agent preference in atopic-eosinophilic severe asthma.
    Tepetam FM; Akyildiz AB; Özden Ş; Örcen C; Yakut T; Atik Ö
    Medicine (Baltimore); 2023 May; 102(18):e33660. PubMed ID: 37144999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals.
    Tuncay G; Damadoglu E; Cihanbeylerden M; Can Bostan O; Kayıkcı H; Özer S; Karakaya G; Kalyoncu AF
    J Asthma; 2023 Oct; 60(10):1885-1894. PubMed ID: 36971076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe asthma concomitant with allergic bronchopulmonary aspergillosis (ABPA) and non-steroid exacerbated respiratory disease (N-ERD) successfully treated with mepolizumab: A case report.
    Çakmak ME
    Tuberk Toraks; 2022 Jun; 70(2):215-219. PubMed ID: 35785889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
    Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
    Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.